Throughout 2018, Lupus News Today brought you coverage of important discoveries, potential disease markers, treatment developments, and clinical trials related…
Articles by Jose Marques Lopes, PhD
The addition of low-dose voclosporin to standard therapy led to significantly greater remission but a higher incidence of adverse…
The levels of galectin-3 binding protein (G3BP) in urine could be used as a biomarker of renal disease activity for…
A low dose of the immunosuppressant leflunomide is as safe and effective as the standard of care cyclophosphamide for induction treatment…
The investigational compound evobrutinib acts on the immune system by promoting anti-inflammatory behavior of macrophages — immune cells that engulf…
Systemic lupus erythematosus (SLE) patients using hydroxychloroquine have a markedly lower risk of a type of abnormal heart rhythm…
Using Benlysta (belimumab) as a maintenance therapy after Rituxan (rituximab) leads to similar kidney function in patients with lupus nephritis compared…
One year of treatment with ustekinumab led to sustained reductions in disease activity in systemic lupus erythematosus (SLE) patients,…
Corticosteroids and hydroxychloroquine are the most common medications used by patients with systemic lupus erythematosus (SLE) or lupus…
The activity of systemic lupus erythematosus (SLE) is persistently high in a large proportion of patients, despite high rates of…